CF PharmTech Closes $90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

According to PRNewswire, CF PharmTech, Inc. ("CF PharmTech"), a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation from new investors CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings, Everest Venture Capital, and existing investors, such as Oriza Holdings, Longmen Venture Capital, GTJA Investment and CMB International.

The completion of this round of funding reflects the strong support from China's investors to fuel high-caliber pharmaceutical companies that have a strong global competitive edge and will allow CF PharmTech to bring products in its pipeline to market.

CF PharmTech is a pharmaceutical company dedicated to respiratory health. Since its inception, the company has already established a state of the art R&D and manufacturing facilities for inhalation products. Currently, CF PharmTech has a growing pipeline of over 20 products that are headed to China and global markets.

With respect to this round of financing, New Alliance Capital Executive Director Lei Cai explained, "CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply."

CR-CP Life Science Fund Managing Director Da Liu explained: "CF PharmTech is one of China's most innovative and pioneering pharmaceutical companies to focus on respiratory disease treatments. As a pharma company, CF PharmTech fully embodies a commitment to quality and global standards. As one of the few leading private pharmaceutical companies of respiratory drug delivery, CF PharmTech has immense potential for growth."

CEC Capital served as the exclusive financial adviser to CF PharmTech during this Series E round of financing. 

Founded in 2008 by Qu Liefeng in Shanghai in China, New Alliance Capital is a venture capital and private equity firm that specializes in the early, growth stage and pre-IPO investments. It primarily invests in high-end manufacturing, technology, advanced agriculture, consumer goods, information, media, energy, recycling, environmental protection, and modern services industry sectors. New Alliance Capital typically invests between $4.71 million and $31.41 million. 

Finova Capital supports and creates enabling opportunities for micro & small business. The company's aim is to reach out to financially excluded unorganized, unreached MSME sector. The company is headquartered in Jaipur and provides the loan to both urban poor and rural poor to meet their productive requirements in starting a new business or for growing an existing business.